Drawing Comparisons for Relevant Therapies in Patients With DLBCL

EP: 1.Part 1: Treatment Options and Relevant Data for Patients With DLBCL

EP: 2.Part 2: Shah Discusses Challenges in Using Lenalidomide Plus Tafasitamab for Patients With DLBCL

EP: 3.Part 3: Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Promise in Patients With DLBCL

EP: 4.Part 1: Kline Discusses Challenges of CAR T-Cell Therapy in R/R DLBCL

EP: 5.Part 2: Loncastuximab Provides Potential Bridge Therapy for R/R DLBCL

EP: 6.Part 3: Kline Discusses the Use of Tafasitamab in Certain Patients with R/R DLBCL

EP: 7.Part 1: Decision-Making for Third-Line Treatment of Transplant-Ineligible DLBCL

EP: 8.Part 2: Real-World Challenges with CAR T-Cell Therapy in DLBCL

EP: 9.Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL

EP: 10.Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

EP: 11.Part 2: Loncastuximab as a Third-Line Therapy for Relapsed/Refractory DLBCL

EP: 12.Part 3: Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

EP: 13.Part 1: Selecting Third-Line Options for DLBCL With CAR T-Cell Therapy

EP: 14.Part 2: Sequencing Loncastuximab and CAR T-Cell Therapy in DLBCL

EP: 15.Part 1: Tafasitamab/Lenalidomide Shows Durable Responses in R/R DLBCL

EP: 16.Part 2: LOTIS-2 Trial Includes High-Risk Patients and CAR T Sequencing in R/R DLBCL

EP: 17.Part 1: Real-World Barriers to CAR T-Cell Therapy in Advanced DLBCL

EP: 18.Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL

EP: 19.Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCL

EP: 20.Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

EP: 21.Efficacy Data Support Loncastuximab as Third-Line DLBCL Treatment

EP: 22.Physicians Discuss Roles of Later-Line Therapies in DLBCL

EP: 23.Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

EP: 24.Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL

EP: 25.Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL

EP: 26.Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL

EP: 27.Physicians Consider Loncastuximab for Older Patients With R/R DLBCL

EP: 28.Bispecific Agents Vs Loncastuximab as Third-Line Therapy for R/R DLBCL

EP: 29.ADC Loncastuximab Shows Signs of Durable Response in R/R DLBCL

EP: 30.Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

EP: 31.Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

EP: 32.Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

EP: 33.Experience and Sequencing Guide Third-Line DLBCL Therapy Selection

EP: 34.Different Options Discussed for DLBCL in Later-Lines of Treatment

EP: 35.Takeaways on Tolerability Challenges With Loncastuximab in DLBCL

EP: 36.Loncastuximab Leads to Responses in DLBCL After Prior CD19 CAR T

EP: 37.Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL

EP: 38.Later-Line CD19 and Bispecific Therapies Considered After CAR T

EP: 39.Community Oncologists Show Comfort With Bispecifics in B-Cell Lymphoma

EP: 40.Hematologists Should Consider What Comes Next for Patients With DLBCL

Now Viewing

EP: 41.Drawing Comparisons for Relevant Therapies in Patients With DLBCL

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in diffuse large B-cell lymphoma (DLBCL).

There are 2 approved bispecific antibodies available, epcoritamab (Epkinly) and glofitamab (Columvi), which have similar efficacy and adverse events (AEs), but differences in administration routes. The main distinction is in treatment duration: glofitamab is fixed, while epcoritamab continues until disease progression.

Brem also mentions potential barriers to these treatments she discussed at a Case-Based Roundtable event, such as access and risk of cytokine release syndrome. She explores alternatives like tafasitamab (Monjuvi) with lenalidomide (Revlimid), referencing the L-MIND trial (NCT02399085), and loncastuximab (Zynlonta), highlighting its payload and dosing schedule, which are unique from other antibody-drug conjugates, based on the LOTIS-2 trial (NCT03589469).

TRANSCRIPTION:

0:10 | The 2 approved agents we have in DLBCL are called epcoritamab and glofitamab. They both have similar response rates with all those caveats of cross-trial comparisons. They have very similar [AE] profiles. They differ slightly in terms of the route of administration—one is intravenous, one is subcutaneous—the dosing schedule, and actually I think the major difference when you're sitting down and counseling a patient, is glofitamab is fixed duration vs epcoritamab at this moment is treat to progression.

0:43 | But there may be a reason that people can't or won't or don't want to receive those therapies. Maybe they're not available at their center, [or] because they have risk of cytokine release syndrome or [because] there is recommended hospitalizations. Maybe there's just no access to those things where they live. We did talk about a couple of alternatives, namely tafasitamab/lenalidomide, so it's a combination of a CD19 antibody with lenalidomide, which is an oral medication. We talked about the L-MIND study, which is a single-arm phase 2 [trial] that led to the approval of that drug.

1:13 | We also talked about a drug called loncastuximab, which is an antibody-drug conjugate. It's a little different than a lot of the ones many of us are used to. In lymphoma, we've used polatuzumab vedotin [Polivy] and brentuximab vedotin [Adcetris]; this one has a different…payload or different toxin conjugated to it, so it has a different [AE] profile. It also targets CD19; actually, that one has a very nice dosing schedule. It's once every 3 weeks. We talked a little bit about the times where people may use that drug, but that was approved based on what's called the LOTIS-2 trial.